Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "non"

1178 News Found

Evonik invests in US based biopharma company ‘Allay Therapeutics’
News | December 13, 2022

Evonik invests in US based biopharma company ‘Allay Therapeutics’

Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks


Steps taken by Govt. to support diabetes patients
Policy | December 12, 2022

Steps taken by Govt. to support diabetes patients

As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years


Biocon Biologics elevates Shreehas Tambe as MD & CEO
People | December 06, 2022

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.


Auretics launched herbal cough syrup ‘Sedoril’
News | December 06, 2022

Auretics launched herbal cough syrup ‘Sedoril’

It offers quick relief in various types of Coughs, Colds and Sore Throat,


Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
News | December 05, 2022

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers


Jemperli RUBY phase III trial met its primary endpoint
Diagnostic Center | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival


Briefs: Piramal Enterprises and Shilpa Medicare
News | December 02, 2022

Briefs: Piramal Enterprises and Shilpa Medicare

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval


AstraZeneca’s Dapagliflozin receives CDSCO approval
Drug Approval | November 30, 2022

AstraZeneca’s Dapagliflozin receives CDSCO approval

Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD